Loading...
Loading...
RVLP| Name | Value |
|---|---|
| Revenues | 8.3M |
| Cost of Revenue | 1.9M |
| Gross Profit | 6.3M |
| Operating Expense | 14.4M |
| Operating I/L | -22.0M |
| Other Income/Expense | -12.7M |
| Interest Income | 0.0M |
| Pretax | -24.0M |
| Income Tax Expense | -0.1M |
| Net Income/Loss | -23.9M |
RVL Pharmaceuticals plc is a specialty pharmaceutical company that develops and commercializes pharmaceutical products targeting underserved patient populations in the ocular and medical aesthetics therapeutic areas. The company's flagship product, Upneeq (RVL-1201), is an oxymetazoline hydrochloride ophthalmic solution designed to treat acquired blepharoptosis in adults. By focusing on the commercialization of Upneeq and other pharmaceutical products, RVL Pharmaceuticals plc generates revenue from the sale of these treatments in the United States, Argentina, and Hungary.
